Tags: minimal residual disease
Delaying the Use of High-Dose Melphalan With Stem Cell Rescue in Multiple Myeloma Is Ready for Prime Time
Abstract: The significant advances made in the treatment of multiple myeloma (MM) have allowed for a paradigm shift away from the early use of high-dose […]
Measurement of Circulating Tumor DNA to Guide Management of Patients with Lymphoma
Abstract In recent years, advances have been made in methods to assess response to therapy in lymphoma. Ideally, response assessment tools should be highly sensitive […]
The Evolving Role of Transplantation in Multiple Myeloma: the Need for a Heterogeneous Approach to a Heterogeneous Disease
Abstract: Autologous stem cell transplant (ASCT) is an established frontline standard of care for the younger, fitter patients with newly diagnosed multiple myeloma (NDMM) who […]
BCL-2 As a Therapeutic Target in Chronic Lymphocytic Leukemia
Abstract: Venetoclax (formerly ABT-199) was recently approved in the United States for the treatment of patients who have relapsed or refractory chronic lymphocytic leukemia (CLL) […]